Anixa Wins First Korean Patent for Breast Cancer Vaccine
SAN JOSE, Calif., June 29, 2026 Anixa Biosciences, Inc. announced that the Korean Ministry of Intellectual Property (MOIP) has...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SAN JOSE, Calif., June 29, 2026 Anixa Biosciences, Inc. announced that the Korean Ministry of Intellectual Property (MOIP) has...
SAN JOSE, Calif., June 11, 2026 Anixa Biosciences, Inc. announced that two of its clinical-stage cancer immunotherapy programs will...
NANTES, France, May 22, 2026 OSE Immunotherapeutics announced positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi®...
Vancouver, British Columbia | January 20, 2026 — BioVaxys Technology Corp. reported positive Phase 1B/2 clinical results from its...
